###### Strengths and limitations of this study

-   This study is the first, large-scale, contemporary, multicentre, observational study reporting the prevalence of functional decline in very old patients hospitalised for acute decompensated heart failure (ADHF).

-   The data for this study were prospectively collected from consecutive patients who had hospital admission due to ADHF in the real-world clinical practice in Japan.

-   This study examines the risk factors of functional decline in very old patients hospitalised for ADHF and whether functional decline during the index hospitalisation was associated with worse postdischarge outcomes.

-   We did not collect data regarding on-site and outpatient rehabilitation and nutritional support.

Introduction {#s1}
============

Functional decline in hospitalised patients is a complex and dynamic process.[@R1] Functional decline during hospitalisation was reported to occur in approximately 30%--50% of patients hospitalised for acute medical illness.[@R2] In the rapidly ageing societies, the number of very old patients hospitalised for acute decompensated heart failure (ADHF) is increasing, and ADHF has become the leading cause of hospitalisation due to acute medical illness. In older patients, functional decline associated with hospitalisation often leads to subsequent inability to live actively and independently.

However, there is a scarcity of data regarding the risk factors of functional decline in very old patients hospitalised for ADHF. Identifying high-risk patients for functional decline during hospitalisation would be useful for its prevention. Furthermore, no previous study has focused on subsequent clinical outcomes in patients with functional decline during hospitalisation. Therefore, we sought to clarify the risk factors for functional decline during hospitalisation in very old patients with ADHF and to compare the 1-year clinical outcomes between the two groups of patients with and without functional decline during hospitalisation for ADHF in a large Japanese observational database of hospitalised patients for ADHF in the real-world clinical practice.

Methods {#s2}
=======

Study design, setting and population {#s2-1}
------------------------------------

The Kyoto Congestive Heart Failure (KCHF) registry is a physician-initiated, prospective, observational, multicentre cohort study that enrolled consecutive patients who were hospitalised for ADHF for the first time between 1 October 2014 and 31 March 2016. These patients were admitted into 19 secondary and tertiary hospitals, including rural and urban as well as large and small institutions, throughout Japan. The study met the conditions of the Japanese ethical guidelines for epidemiological study and the US policy for protecting human research participants.[@R6] This study followed the Strengthening the Reporting of Observational Studies in Epidemiology reporting guideline.

The details of the KCHF study design and patient enrolment are described elsewhere.[@R8] Briefly, we enrolled all patients with ADHF, as defined by the modified Framingham criteria, who were admitted to the participating hospitals and patients who underwent heart failure-specific treatment involving intravenous drugs within 24 hours after hospital presentation. Patient records were anonymised before analysis. Data analysis was conducted from August 2018 to October 2018.

Among 4056 patients enrolled in the KCHF registry, 3785 patients were discharged alive after hospitalisation for ADHF. Clinical follow-up data were collected in October 2017. The attending physicians or research assistants at each participating hospital collected clinical events after the index hospitalisation from hospital charts or by contacting patients, their relatives or their referring physicians with consent. The present analysis had two objectives. First, we sought to clarify the risk factors for functional decline during hospitalisation of patients with ADHF. Second, we sought to compare the 1-year clinical outcomes between the two groups of patients with and without functional decline during the hospitalisation for ADHF. Among 4056 patients enrolled in the KCHF registry, the current study population consisted of 3555 patients who were discharged alive and were assessed for functional decline during hospitalisation, excluding 271 patients who died during the index hospitalisation, 99 patients whose functional status before admission and/or at discharge was not available, and 131 patients who were bedridden before index hospitalisation ([figure 1](#F1){ref-type="fig"}). The long-term follow-up was censored at 1 year. The primary outcome measure in the current analysis was a composite of all-cause death or heart failure hospitalisation at 1 year. The secondary outcome measures were all-cause death, heart failure hospitalisation, and a composite of all-cause death or all-cause hospitalisation at 1 year.

![Patient flow chart. ADHF, acute decompensated heart failure; KCHF, Kyoto Congestive Heart Failure.](bmjopen-2019-032674f01){#F1}

Definitions {#s2-2}
-----------

Physical activity before admission and at discharge was classified by mobility status based on the definition of the Japanese long-term care insurance into ambulatory (including those patients using any aid such as stick), use of wheelchair outdoor only, use of wheelchair indoor and outdoor, and bedridden state.[@R8] Functional decline was defined as the decline of at least one stage on physical activity at discharge compared with preadmission status. In-hospital worsening heart failure was defined as additional intravenous drug administration for heart failure, haemodialysis, or mechanical circulatory or respiratory support, occurring \>24 hours after therapy initiation.[@R12] In-hospital worsening renal function was defined as \>0.3 mg/dL increase in serum creatinine levels during the index hospitalisation.[@R13] Detailed definitions of baseline clinical characteristics including the signs and symptoms of heart failure have been described previously.[@R9] Missing values are presented in [online supplementary eTable 1](#SP1){ref-type="supplementary-material"}.
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Statistical analysis {#s2-3}
--------------------

Categorical variables were presented as numbers with percentages and compared using χ^2^ test. Continuous variables were expressed as mean with SD or median with 25th--75th percentiles, and compared using the Student's t-test when normally distributed or Wilcoxon rank-sum test when not normally distributed.

We compared baseline characteristics and clinical outcomes based on the presence or absence of functional decline during the index hospitalisation. A multivariable logistic regression model was developed to identify clinical characteristics associated with an increased risk for functional decline. We used 24 clinically relevant factors listed in [table 1](#T1){ref-type="table"} as potential independent risk factors in multivariable logistic regression models and estimated the OR and 95% CI. We used the Kaplan-Meier method to estimate the cumulative 1-year incidences of the outcome measures and assessed the differences with the log-rank test. We expressed the associations of the functional decline group with the no functional decline group for all outcome measures as HR with 95% CI by multivariable Cox proportional hazard models, incorporating 30 clinically relevant risk-adjusting variables indicated in [table 1](#T1){ref-type="table"}. We also conducted subgroup analyses stratified by age, sex, left ventricular ejection fraction (LVEF), anaemia, albumin levels, body temperature and the symptomatic status at discharge (oedema and general malaise at discharge). In the multivariable analysis and subgroup analyses, continuous variables were dichotomised by clinically meaningful reference values or median values: age ≥80 years based on the median value, LVEF \<40% based on the heart failure guideline of LVEF classification,[@R16] body mass index ≤22 kg/m^2^, renal dysfunction (estimated glomerular filtration rate \<30 mL/min/1.73 m^2^) based on chronic kidney disease grade, decreased albumin levels (serum albumin \<3.0 g/dL), hyponatraemia (serum sodium \<135 mEq/L), and elevated body temperature (body temperature ≥37.5°C) based on the cut-off value in metabolic syndrome.[@R17]

###### 

Patient characteristics

                                             Functional decline      No functional decline   P value
  ------------------------------------------ ----------------------- ----------------------- ----------
  Clinical characteristics                                                                   
   Age, years                                85 (80--89)             79 (70--85)             \<0.001
    ≥80 years\*†                             399 (76)                1407 (46)               \<0.001
   Women\*†                                  294 (56)                1278 (42)               \<0.001
   BMI, kg/m^2^                              22.0±4.0                23.1±4.5                \<0.001
    ≤22 kg/m^2^\*†                           269 (55)                1281 (44)               \<0.001
  Medical history                                                                            
   Heart failure hospitalisation\*†          186 (36)                1077 (36)               0.92
   Atrial fibrillation or flutter            220 (42)                1263 (42)               0.98
   Hypertension\*†                           406 (77)                2174 (72)               0.02
   Diabetes mellitus\*†                      187 (35)                1145 (38)               0.29
   Myocardial infarction\*†                  112 (21)                681 (23)                0.51
   Stroke\*†                                 125 (24)                432 (14)                \<0.001
   Currently smoking\*†                      28 (5.5)                425 (14)                \<0.001
   Malignancy                                97 (18)                 419 (14)                0.006
   Chronic lung disease\*†                   41 (7.8)                247 (8.2)               0.76
   Dementia\*†                               175 (33)                423 (14)                \<0.001
  Social background on admission                                                             
   Poor medical adherence                    100 (19)                498 (16)                0.16
   Living alone\*†                           127 (24)                652 (22)                0.20
   Public assistance                         24 (4.6)                186 (6.1)               0.14
  Functional status before admission                                                         
   Ambulatory\*†                             420 (80)                2529 (84)               0.02
   Use of wheelchair (outdoor only)          80 (15)                 192 (6.3)               \<0.001
   Use of wheelchair (outdoor and indoor)    28 (5.3)                306 (10)                \<0.001
  Origin                                                                                     
   Ischaemic                                 134 (25)                820 (27)                0.41
   Acute coronary syndrome\*†                36 (6.8)                166 (5.5)               0.22
   Hypertensive                              131 (25)                754 (25)                0.96
   Valvular                                  124 (23)                565 (19)                \<0.001
   Cardiomyopathy                            54 (10)                 492 (16)                \<0.001
  Vital signs and symptoms on presentation                                                   
   BP, mm Hg                                                                                 
   Systolic BP                               144±32                  149±35                  0.003
    Systolic BP ≥140 mm Hg                   275 (53)                1741 (58)               0.03
    Systolic BP \<90 mm Hg\*†                12 (2.3)                76 (2.5)                0.76
   Diastolic BP                              81±23                   86±24                   \<0.001
   Heart rate, beats/min                     93±27                   96±28                   0.001
    \<60 beats/min\*†                        44 (8.5)                195 (6.5)               0.11
   Body temperature, °C                      36.6±0.7                36.5±0.6                \<0.001
    ≥37.5 °C\*†                              58 (11)                 154 (5.3)               \<0.001
   Rhythms on presentation                                                                   
    Sinus rhythm                             280 (53)                1715 (57)               0.12
    Atrial fibrillation or flutter\*†        198 (38)                1085 (36)               0.47
   NYHA class III or IV\*†                   482 (92)                2598 (73)               \<0.001
  Tests on admission                                                                         
   LVEF                                      48±16                   46±16                   0.02
    HFrEF (EF \<40%)\*†                      167 (32)                1148 (38)               0.006
    HFmrEF (EF 40%--49%)                     117 (22)                566 (19)                0.06
    HFpEF (EF ≥50%)                          242 (46)                1305 (43)               0.24
   Haemoglobin, g/L                          110±21                  117±24                  \<0.001
    Anaemia\*†‡                              401 (76)                1946 (64)               \<0.001
   BNP, pg/mL                                782 (448--1410)         687 (375--1214)         \<0.001
   NT-proBNP, pg/mL                          10 795 (3450--18 000)   5416 (2629--11 438)     0.001
   Creatinine, mg/dL                         1.2 (0.8--1.6)          1.1 (0.8--1.6)          0.21
   eGFR, mL/min/1.73 m^2^                    38 (24--54)             46 (30--62)             \<0.001
    \<30 mL/min/1.73 m^2^\*†                 195 (37)                747 (25)                \<0.001
   Blood urea nitrogen, mg/dL                28 (20--39)             23 (17--33)             \<0.001
   Albumin, g/dL                             3.3±0.5                 3.5±0.5                 \<0.001
    \<3.0 g/dL\*†                            112 (22)                332 (11)                \<0.001
   Sodium, mEq/L                             138±4.7                 139±4.1                 \<0.001
    \<135 mEq/L\*†                           83 (16)                 325 (11)                0.001
   Potassium, mEq/L                          4.3±0.8                 4.2±0.6                 0.03
  Clinical signs and symptoms at discharge                                                   
   Oedema†                                   89 (17)                 320 (11)                \<0.001
   General malaise†                          152 (31)                388 (14)                \<0.001
  Medications at discharge                                                                    
   Number of drugs prescribed                8 (6--11)               9 (6--11)               0.12
   Loop diuretics†                           428 (81)                2472 (82)               0.74
   ACEI or ARB†                              242 (46)                1838 (61)               \<0.001
   MRA†                                      208 (39)                1409 (47)               0.002
   Beta blocker†                             287 (54)                2101 (69)               \<0.001
   Tolvaptan                                 76 (14)                 299 (9.9)               0.002
  Functional status at discharge                                                             
   Ambulatory                                0                       2682 (89)               \<0.001
   Use of wheelchair (outdoor only)          184 (35)                160 (5.3)               \<0.001
   Use of wheelchair (outdoor and indoor)    261 (49)                185 (6.1)               \<0.0001
   Bedridden                                 83 (16)                 0                       \<0.001
  Living place after discharge                                                               
   Home                                      247 (47)                2709 (90)               \<0.001
   Hospital                                  225 (43)                180 (6.0)               \<0.001
   Institution for the aged                  50 (9.5)                114 (3.8)               \<0.001
   Other                                     4 (0.8)                 17 (0.6)                0.59

Continuous variables are presented as mean±SD or median with (IQR). Categorical variables are presented as number (percentage).

\*Risk-adjusting variables were selected for multivariable logistic regression models.

†Risk-adjusting variables were selected for multivariable Cox proportional hazard models.

‡Defined by the WHO criteria (haemoglobin \<12 g/dL for women and \<13 g/dL for men).

ACEI, ACE inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; BNP, brain-type natriuretic peptide; BP, blood pressure; EF, ejection fraction; eGFR, estimated glomerular filtration rate; HFmrEF, heart failure with mid-range ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; NT-proBNP, N-terminal-proBNP; NYHA, New York Heart Association.

We performed an additional analysis including data of those patients who died during the index hospitalisation and those who were bedridden before the index hospitalisation, and evaluated the factors associated with functional decline or in-hospital mortality by constructing the multivariable adjusted Cox models. All statistical analyses were conducted by a physician (HY) and a statistician (TM) using JMP V.13.0 or SAS V.9.4. Two-tailed p values less than 0.05 were considered statistically significant.

Patient and public involvement {#s2-4}
------------------------------

No patients were involved.

Results {#s3}
=======

Baseline clinical characteristics {#s3-1}
---------------------------------

Among 3555 study patients, physical activity before admission included ambulatory in 2949 patients (83%), use of wheelchair outdoor only in 272 patients (7.7%), and use of wheelchair outdoor and indoor in 334 patients (9.4%). At hospital discharge, functional decline was observed in 420 patients (14%) who were ambulatory before admission, in 80 patients (29%) who had used wheelchair outdoor only, and in 28 patients (8.4%) who had used wheelchair outdoor and indoor. Consequently, decline in functional status was observed in 528 patients (15%; functional decline group), while functional decline was not observed in 3027 patients (85%; no functional decline group) ([online supplementary eFigure 1](#SP1){ref-type="supplementary-material"}). Use of wheelchair outdoor only before admission was more prevalent in the functional decline group than in the no functional decline group; however, 80% of patients in the functional decline group were ambulatory before admission ([table 1](#T1){ref-type="table"}).

Regarding the baseline clinical characteristics, the patients in the functional decline group were older and had a higher prevalence of hypertension, prior stroke, renal dysfunction, dementia, malignancy, anaemia, decreased albumin levels and hyponatraemia ([table 1](#T1){ref-type="table"}). There were no significant differences in previous heart failure hospitalisation, atrial fibrillation or flutter, previous myocardial infarction, chronic lung disease, and living alone status as a social background between the two groups ([table 1](#T1){ref-type="table"}). The functional decline group was more likely to have a valvular aetiology, lower blood pressure, lower heart rate, higher levels of brain natriuretic peptide (BNP) or N-terminal portion of proBNP, and a higher LVEF ([table 1](#T1){ref-type="table"}). The proportion of patients who achieved relief of signs and symptoms on admission after treatment in the emergency room was not significantly different between the two groups (14% vs 16%, p=0.25).

Risk factors for functional decline {#s3-2}
-----------------------------------

Among the baseline characteristics and status on hospital presentation, the following independent risk factors for functional decline during hospitalisation were identified by the multivariable logistic regression analysis: age ≥80 years (OR 2.71; 95% CI 2.09 to 3.51), female (OR 1.32; 95% CI 1.05 to 1.67), prior stroke (OR 1.67; 95% CI 1.28 to 2.19), dementia (OR 2.26; 95% CI 1.74 to 2.95), ambulatory before admission (OR 1.74; 95% CI 1.29 to 2.35), elevated body temperature (OR 1.91; 95% CI 1.31 to 2.79), New York Heart Association class III or IV on admission (OR 1.54; 95% CI 1.07 to 2.22), decreased albumin levels (OR 1.76; 95% CI 1.32 to 2.34), hyponatraemia (OR 1.49; 95% CI 1.10 to 2.03) and renal dysfunction (OR 1.55; 95% CI 1.22 to 1.98) ([figure 2](#F2){ref-type="fig"}).

![Clinical factors associated with functional decline during hospitalisation in the univariate and multivariable logistic regression models. BP, blood pressure; BMI, body mass index; eGFR, estimated glomerular filtration rate; HF, heart failure; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association.](bmjopen-2019-032674f02){#F2}

In-hospital adverse events and status at discharge {#s3-3}
--------------------------------------------------

The median length of hospital stay was longer in the functional decline group than in the no functional decline group (21 days vs 15 days, p\<0.001). Regarding in-hospital adverse events, the prevalence of worsening heart failure, worsening renal function and stroke was higher in the functional decline group than in the no functional decline group ([table 2](#T2){ref-type="table"}). The proportion of patients with symptoms such as oedema and general malaise at discharge was higher in the functional decline group than in the no functional decline group ([table 1](#T1){ref-type="table"}). Consequently, the proportion of patients in the functional decline group discharged to home was also lower (47% vs 90%, p\<0.001). Regarding medical treatment at discharge, ACE inhibitor or angiotensin receptor blocker, and beta blocker were less often prescribed in the functional decline group than in the no functional decline group ([table 1](#T1){ref-type="table"}).

###### 

In-hospital management and outcome

                                                                   Functional decline   No functional decline   P value
  ---------------------------------------------------------------- -------------------- ----------------------- ---------
  In-hospital management                                                                                        
   Management in the emergency room                                                                             
    Respiratory management                                                                                      
    Oxygen inhalation                                              295 (56)             1382 (46)               \<0.001
    NIPPV                                                          82 (16)              423 (14)                0.35
    Intubation                                                     11 (2.1)             53 (1.8)                0.60
   Intravenous drugs within 24 hours after hospital presentation                                                
    Inotropes                                                      101 (19)             405 (13)                \<0.001
    Furosemide                                                     446 (85)             2536 (84)               0.69
  In-hospital clinical outcomes                                                                                 
   In-hospital adverse events                                                                                   
    Stroke                                                         27 (5.1)             26 (0.9)                \<0.001
    Worsening heart failure                                        130 (25)             490 (16)                \<0.001
    Worsening renal function                                       244 (47)             992 (33)                \<0.001
    In-hospital infection                                          104 (20)             258 (8.5)               \<0.001
   Length of stay, days                                            21 (14--37)          15 (11--22)             \<0.001

NIPPV, non-invasive intermittent positive pressure ventilation.

Long-term outcomes: functional decline versus no functional decline groups {#s3-4}
--------------------------------------------------------------------------

The follow-up rate at 1 year was 96%. The cumulative 1-year incidence of the primary outcome measure (a composite of all-cause death or heart failure hospitalisation) in the functional decline group was significantly higher than that in the no functional decline group (49% vs 31%, log-rank p\<0.001) ([figure 3](#F3){ref-type="fig"}). After adjusting for baseline characteristics, the higher risk of the functional decline group relative to the no functional decline group remained significant (adjusted HR, 1.46; 95% CI, 1.24 to 1.71; p\<0.001) ([figure 3](#F3){ref-type="fig"} and [table 3](#T3){ref-type="table"}). The cumulative 1-year incidence of all-cause death was also significantly higher in the functional decline group than in the no functional decline group. Even after adjusting for confounders, the excess mortality risk of the functional decline group relative to the no functional decline group remained significant ([figure 3](#F3){ref-type="fig"} and [table 3](#T3){ref-type="table"}). The cumulative 1-year incidence of heart failure hospitalisation was also significantly higher in the functional decline group than in the no functional decline group. However, the adjusted risk of the functional decline group relative to the no functional decline group for heart failure hospitalisation was no longer significant ([figure 3](#F3){ref-type="fig"} and [table 3](#T3){ref-type="table"}). The cumulative 1-year incidence of a composite of all-cause death or all-cause hospitalisation was significantly higher in the functional decline group than in the no functional decline group. After adjusting for confounders, the higher risk of the functional decline group relative to the no functional decline group remained significant ([figure 3](#F3){ref-type="fig"} and [table 3](#T3){ref-type="table"}). In the subgroup analyses, there were no interactions between those subgroup factors and the association of functional decline with the primary outcome measure ([online supplementary eFigure 2](#SP1){ref-type="supplementary-material"}).

![Cumulative incidence for the primary outcome measure (A), all-cause death (B), HF hospitalisation (C), and a composite of all-cause death or all-cause hospitalisation (D), according to the presence or absence of functional decline. HF, heart failure.](bmjopen-2019-032674f03){#F3}

###### 

Clinical outcomes in the entire cohort

  -----------------------------------------------------------------------------------------------------------------------------------------------------------
  Outcomes                                       Functional decline   No functional decline   Unadjusted HR\        P value   Adjusted HR\          P value
                                                                                              (95% CI)                        (95% CI)              
  ---------------------------------------------- -------------------- ----------------------- --------------------- --------- --------------------- ---------
  All-cause death or HF hospitalisation          243/528 (49)         902/3027 (31)           1.95 (1.71 to 2.21)   \<0.001   1.46 (1.24 to 1.71)   \<0.001

  All-cause death                                174/528 (36)         386/3027 (13)           3.02 (2.58 to 3.53)   \<0.001   2.12 (1.74 to 2.58)   \<0.001

  HF hospitalisation                             116/528 (28)         663/3027 (23)           1.25 (1.04 to 1.50)   0.02      1.03 (0.83 to 1.28)   0.81

  All-cause death or all-cause hospitalisation   279/528 (57)         1186/3027 (40)          1.69 (1.50 to 1.91)   \<0.001   1.39 (1.20 to 1.61)   \<0.001
  -----------------------------------------------------------------------------------------------------------------------------------------------------------

The number of patients with at least one event was counted through the 1-year follow-up period.

HF, heart failure.

Additional analysis on the risk factors for functional decline or in-hospital mortality {#s3-5}
---------------------------------------------------------------------------------------

The risk factors for functional decline or in-hospital mortality in a total of 4056 patients were similar to the risk factors for functional decline. LVEF \<40% (OR 1.24; 95% CI 1.00 to 1.52; p=0.047) and acute coronary syndrome (OR 1.76; 95% CI 1.19 to 2.60; p=0.005) which were not included as risk factors for functional decline emerged as risk factors for functional decline or in-hospital mortality ([online supplementary eTable 2](#SP1){ref-type="supplementary-material"}). Meanwhile, among the risk factors for functional decline, being female (OR 1.13; 95% CI 0.93 to 1.38; p=0.22) was not included as a risk factor for functional decline or in-hospital mortality ([figure 2](#F2){ref-type="fig"} and [online supplementary eTable 2](#SP1){ref-type="supplementary-material"}).

Discussion {#s4}
==========

The main findings of the present study investigating the prevalence and risk factors of functional decline during hospitalisation and its relationship with postdischarge outcomes in patients with ADHF hospitalisation were as follows: (1) functional decline during ADHF hospitalisation occurred in 15% of patients, and 80% of those with functional decline were ambulatory before admission; (2) the independent baseline risk factors associated with functional decline included age ≥80 years, female, prior stroke, dementia, ambulatory before admission, elevated body temperature, New York Heart Association class III or IV on admission, decreased albumin levels, hyponatraemia and renal dysfunction; and (3) functional decline during the index hospitalisation was associated with higher long-term risk for a composite of all-cause death or heart failure hospitalisation.

This is the first, large-scale, contemporary, multicentre study reporting the prevalence of functional decline in patients hospitalised for ADHF. Of note, we identified the severity of symptoms or patient status specific for heart failure was associated with functional decline independent of well-known factors in acute medical illness.[@R18] Functional decline is an inevitable consequence in aged people, but hospitalisation accelerates the decline.[@R20] Functional declines have been found to be related not only to impairment of independence and quality of life (QOL), but also to increased health service use, higher risk for institutionalisation and higher risk for mortality.[@R23] Indeed, in the present study, the proportion of patients discharged to home was lower in the functional decline group than in the no functional decline group, suggesting impaired QOL after discharge. Also, long-term mortality was worse in the functional decline group than in the no functional decline group. Therefore, it is important to recognise risk factors of functional decline. In previous studies of hospitalised patients with acute medical illness, the predictors of functional decline in hospitalised elderly patients were older age, admission diagnosis, lower functional status, impaired cognitive status, comorbidities and length of hospital stay.[@R18] These findings were confirmed in the setting of ADHF in our present study. In addition, findings specific for ADHF such as the dyspnoea or hyponatraemia were associated with functional decline, which were also reported to be risk factors for in-hospital mortality in ADHF.[@R28] The prevalence of oedema and general malaise at discharge was higher in the functional decline group. Early achievement of successful ADHF treatment might reduce the risk of functional decline, although the present observational study could not address the cause--effect relationship between the functional decline and the symptomatic status at discharge.

There might be several possible strategies to prevent functional decline during ADHF hospitalisation. The first is the early improvement of haemodynamic status to avoid worsening heart failure. The prevalence of worsening heart failure was higher in the functional decline group. As functional decline associated with hospitalisation begins within 48 hours of admission, early improvement of heart failure to reduce the incidence of hospitalisation-associated disability is one of the main goals of care.[@R28] Second, it would be important to be adequately aware that providing aggressive interventions prevents functional decline in high-risk patients. We identified the risk factors among the baseline characteristics in patients with ADHF. In addition, the adverse events during hospitalisation may be tightly related to the functional decline. Stroke is one of the causes of functional decline and is observed in 5.1% of patients with functional decline. Third, seamless rehabilitation and comprehensive geriatric management through a multidisciplinary team approach might be a strategy for the prevention of functional decline.[@R29] In addition, the subgroup analysis showed that there were no interactions between those subgroup factors and the association of functional decline with the primary outcome measure. Thus, prevention of functional decline would have an impact on improving outcomes in all patients with ADHF. One possible strategy could be immediate, tailored physical function rehabilitation during and after heart failure hospitalisation.[@R33]

Limitations {#s4-1}
-----------

This study has several limitations. First, we adopted simple classification of functional status based on the definition of the Japanese long-term care insurance: ambulatory, use of wheelchair outdoor only, use of wheelchair indoor and outdoor, and bedridden state. The categorisation scheme is an easy-to-understand but coarse measure with very large gradations inherent in each single stage and therefore very likely substantially underestimated the prevalence of meaningful functional decline. Second, we did not collect data regarding on-site and outpatient rehabilitation and nutritional support. However, a team-based approach for patients with heart failure was adapted in all the participating centres in the present study. Third, we did not include the status at discharge or adverse in-hospital events in the analysis for the risk factor for functional decline, because the cause--effect relationship was not clear. Fourth, data on postdischarge medication and change of functional status after discharge from the index hospitalisation were not collected and not analysed in the analysis for the long-term outcomes. Fifth, as with any observational study, the possibility of selection bias and residual confounding cannot be excluded, although we adjusted for 29 variables as most conceivable confounders.

Conclusions {#s5}
===========

The independent risk factors of functional decline in patients with ADHF were related to both frailty and severity of heart failure. Functional decline during ADHF hospitalisation was associated with unfavourable postdischarge outcomes.
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